Overall survival · patients with extensive SCLC without previous treatment
1 finding from 1 review
Adverse effects · patients with extensive SCLC without previous treatment
1 finding from 1 review
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
3 findings from 1 review
RR 1.07 [0.91, 1.25]
4 studies · 541 participants
Moderate
RR 1.06 [0.97, 1.17]
3 studies · 761 participants
Moderate
RR 0.96 [0.65, 1.41]
2 studies · 219 participants
Moderate
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).
3 findings from 1 review
RR 1.07 [0.75, 1.54]
1 study · 141 participants
Low
RR 0.86 [0.55, 1.37]
1 study · 141 participants
Low
RR 0.89 [0.51, 1.55]
1 study · 141 participants
Low
3‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
3‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).
1 finding from 1 review
Overall survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
Summary of findings table (subcomparison 2): second‐line… probably leads to lower overall survival compared with control intervention alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
Summary of findings table (subcomparison 2): second‐line… may leads to lower progression‐free survival compared with control intervention alone (low certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
1 finding from 1 review
Overall survival (OS) · patients with resectable gastric cancer
Post‐surgical chemotherapy leads to lower overall Survival (OS) compared with surgery alone (high certainty).
1 finding from 1 review
Disease-free survival · patients with resectable gastric cancer
Post‐surgical chemotherapy leads to lower disease Free Survival compared with surgery alone (high certainty).
1 finding from 1 review
Overall survival · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 to 4 anaemia compared with chemotherapy alone (low certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).
2 findings from 1 review